Skip to content

Recombinant human bone morphogenetic protein-2 plus cannulated compression screws as the treatment for femoral neck fracture of young adults: a prospective, multicenter, randomized, controlled clinical trial

Recombinant human bone morphogenetic protein-2 plus cannulated compression screws as the treatment for femoral neck fracture of young adults: a prospective, multicenter, randomized, controlled clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072199
Enrollment
Unknown
Registered
2023-06-06
Start date
2025-05-17
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femoral Neck Fracture

Interventions

Test arm:cannulated compression screws+2mg of rhBMP-2
Control arm:cannulated compression screws

Sponsors

The Third Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Willing to join the study and sign the informed consent form; 2. Male or female patients aged 18-40 years; 3. Those who have a clear history of trauma, are definitely diagnosed as a new Garden III or above neck of femur fracture by imaging examination, and plan to receive hollow screw internal fixation; 4. Admission to hospital after injury <= 72 h.

Exclusion criteria

Exclusion criteria: 1. Previous hip surgery, ipsilateral hip or femoral dysplasia; 2. Multiple injuries (such as injury severity scale ISS > 16) or accompanied by ipsilateral lower limb fractures, femoral head fractures, pelvic or acetabular fractures; 3. Pathological or old fractures (injury to surgery >= 2 weeks); 4. Patients with other diseases affecting surgery and rehabilitation, such as metabolic bone disease, poliomyelitis sequelae, sequelae of poliomyelitis, a history of poor bone union,and diabetes; 5.A history of endocrine or metabolic disorders known to affect osteogenesis (e.g., renal osteodystrophy, hyperthyroidism, parathyroid disorders, Ehler-Danlos syndrome, osteogenesis imperfecta, calcium imbalance) 6. Patients with severe cardiac and renal insufficiency, liver damage, hematopoietic dysfunction, and severe tumor history; 7. Patients who received open reduction during surgery; 8. Patients with obvious surgical contraindications; 9. Patients who require systemic glucocorticoid therapy; 10. Pregnant or lactating women, as well as those who plan to conceive during the trial period.

Design outcomes

Secondary

MeasureTime frame
rate of fracture union;Harris hip score;Surgical complications;

Primary

MeasureTime frame
time of fracture union ;

Countries

China

Contacts

Public ContactZhiyong Hou

The Third Hospital of Hebei Medical University

drzyhou@gmail.com+86 185 3311 2800

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026